eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

3/2018
vol. 43
 
Share:
Share:
more
 
 
abstract:
Clinical immunology

Diversity of dendritic cells generated from umbilical cord or adult peripheral blood precursors

Magdalena Szaryńska, Krzysztof Preis, Piotr Zabul, Zbigniew Kmieć

(Centr Eur J Immunol 2018; 43 (3): 306-313)
Online publish date: 2018/10/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Following the discovery of methods to generate large numbers of specific dendritic cells (DCs) ex vivo, the possibility of exploiting these cells in immunotherapeutic strategies will become a reality. It seems to be rationally to analyse the influence of the precursor source for further features and applications.

For the needs of the given project DCs were derived from precursors derived from adult peripheral blood (APB) and umbilical cord blood (UCB). During some expansions of UCB CD34+ cells were separated giving non-adherent DCs (NA-DCs) or adherent DCs (A-DCs), whereas DCs derived from UCB precursors without separation gave rise to All-DCs. DC subpopulations were stimulated by lipopolysaccharides (LPS) or interferon- (IFN-), and afterwards the morphology, phenotype, and stimulatory properties were analysed.

Our findings demonstrated that DCs generated from APB and UCB precursors were not equivalent and exhibited opposite features when expanded in comparable conditions. Additionally, all three subpopulations of UCB-derived DCs presented functional dissimilarities. Based on our results we concluded that the precursor source and the composition of media must be considered as crucial to the success of potential therapeutic application.
keywords:

dendritic cells, haematopoietic stem cells, monocytes

references:
Han S, Wang Y, Wang B, et al. (2010): Ex vivo development, expansion and in vivo analysis of a novel lineage of dendritic cells from hematopoietic stem cells. J Immune Based Ther Vaccines 8: 8.
Chiang CL, Maier DA, Kandalaft LE, et al. (2011): Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. J Transl Med 9: 198.
Syme R, Bajwa R, Robertson L, et al. (2005): Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral blood from cancer patients. Stem Cells 23: 74-81.
Harada Y, Okada-Nakanishi Y, Ueda Y, et al. (2011): Cytokine-based high log-scale expansion of functional human dendritic cells from cord-blood CD34-positive cells. Sci Rep 1: 174.
Balan S, Kale VP, Limaye LS (2009): A simple two-step culture system for the large-scale generation of mature and functional dendritic cells from umbilical cord blood CD34+ cells. Transfusion 49: 2109-2121.
Li Y, Liu M, Yang ST (2014): Dendritic cells derived from pluripotent stem cells: Potential of large scale production. World J Stem Cells 6: 1-10.
Lakomy D, Janikashvili N, Fraszczak J, et al. (2011): Cytotoxic dendritic cells generated from cancer patients. J Immunol 187: 2775-2782.
Bracho F, van de Ven C, Areman E, et al. (2003): A comparison of ex vivo expanded DCs derived from cord blood and mobilized adult peripheral blood plastic-adherent mononuclear cells: decreased alloreactivity of cord blood DCs. Cytotherapy 5: 349-361.
Shi J, Ikeda K, Fujii N, et al. (2005): Activated human umbilical cord blood dendritic cells kill tumor cells without damaging normal hematological progenitor cells. Cancer Sci 96: 127-133.
Xu RL, Tang Y, Ogburn PL, et al. (2004): Implication of delayed TNF-αlpha exposure on dendritic cell maturation and expansion from cryopreserved cord blood CD34+ hematopoietic progenitors. J Immunol Methods 293:169-182.
Ballestrero A, Boy D, Moran E, et al. (2008): Immunotherapy with dendritic cells for cancer. Adv Drug Deliv Rev 60: 173-183.
Palucka K, Ueno H, Fay J, Banchereau J (2011): Dendritic cells and immunity against cancer. J Intern Med 269: 64-73.
Broxmeyer HE, Srour EF, Hangoc G, et al. (2003): High-efficiency recovery of functional hematopoietic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl Acad Sci U S A 100: 645-650.
Kurtzberg J. (2009): Update on umbilical cord blood transplantation. Curr Opin Pediatr 21: 22-29.
Kurtzberg J, Prasad VK, Carter SL, et al. (2008): Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies. Blood 112: 4318-4327.
Ferlazzo G, Wesa A, Wei WZ, Galy A. (1999): Dendritic cells generated either from CD34+ progenitor cells or from monocytes differ in their ability to activate antigen-specific CD8+ T cells. J Immunol 163: 3597-3604.
Liu EM, Law HK, Lau YL (2010): Mycobacterium bovis bacillus Calmette-Guerin treated human cord blood monocyte-derived dendritic cells polarize naive T cells into a tolerogenic phenotype in newborns. World J Pediatr 6: 132-140.
Mellor AL, Baban B, Chandler P, et al. (2003): Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 171: 1652-1655.
Miller G, Pillarisetty VG, Shah AB, et al. (2003): Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties. J Immunol 170: 3554-3564.
Chen B, Stiff P, Sloan G, et al. (2001): Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli. Clin Immunol 98: 280-292.
Zheng Z, Takahashi M, Narita M, et al. (2000): Generation of dendritic cells from adherent cells of cord blood by culture with granulocyte-macrophage colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha. J Hematother Stem Cell Res 9: 453-464.
Mortarini R, Anichini A, Di Nicola M, et al. (1997): Autologous dendritic cells derived from CD34+ progenitors and from monocytes are not functionally equivalent antigen-presenting cells in the induction of melan-A/Mart-1(27-35)-specific CTLs from peripheral blood lymphocytes of melanoma patients with low frequency of CTL precursors. Cancer Res 57: 5534-5541.
Liu S, Yu Y, Zhang M, et al. (2001): The involvement of TNF-αlpha-related apoptosis-inducing ligand in the enhanced cytotoxicity of IFN-beta-stimulated human dendritic cells to tumor cells. J Immunol 166: 5407-5415.
Chapoval AI, Tamada K, Chen L (2000): In vitro growth inhibition of a broad spectrum of tumor cell lines by activated human dendritic cells. Blood 95: 2346-2351.
Arrighi JF, Hauser C, Chapuis B, et al. (1999): Long-term culture of human CD34(+) progenitors with FLT3-ligand, thrombopoietin, and stem cell factor induces extensive amplification of a CD34(-)CD14(-) and a CD34(-)CD14(+) dendritic cell precursor. Blood 93: 2244-2252.
Caux C, Massacrier C, Vanbervliet B, et al. (1997): CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood 90: 1458-1470.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe